KURA - Kura Oncology, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$22.57
DETAILS
HIGH:
$24.00
LOW:
$15.00
MEDIAN:
$24.00
CONSENSUS:
$22.57
UPSIDE:
114.14%
About Kura Oncology, Inc. (https://kuraoncology.com)
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Troy Edward Wilson | Chairman, Chief Executive Officer & President | 1969 | $1,437,766 USD |
| Kathleen Ford | Chief Operating Officer | 1947 | $926,501 USD |
| Mollie Leoni | Chief Medical Officer | 1978 | $855,297 USD |
| Brian T. Powl | Chief Commercial Officer | 1974 | $814,998 USD |
| Teresa Brophy Bair | Chief Legal Officer & Corporate Secretary | 1971 | $745,021 USD |
| Francis J. Burrows | Chief Scientific Officer | 1962 | – |
| Greg Mann | Senior Vice President of Investor Relations & Corporate Affairs | – | – |
| Roger Bakale | Senior Vice President of Manufacturing & Supply Chain | – | – |
| Samir Vattompadam | Senior Vice President of Global Program Leadership | – | – |
| Thomas Doyle | Senior Vice President of Finance & Accounting | 1971 | – |